Products
Pre-made Derlotuximab benchmark antibody ( Whole mAb Radiolabelled, anti-DNA;H1 Complex therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-143
Pre-made Derlotuximab benchmark antibody (Whole mAb Radiolabelled, anti-DNA;H1 Complex therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Iodine (131 I) derlotuximab biotin is a monoclonal antibody designed for the treatment of recurrent glioblastoma multiforme. This drug was developed by Peregrine Pharmaceuticals, Inc.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-143-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-143-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-143-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-143-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Derlotuximab biosimilar, Whole mAb Radiolabelled: Anti-DNA/H1 Complex therapeutic antibody |
| INN Name | Derlotuximab |
| Target | DNA;H1 Complex |
| Format | Whole mAb Radiolabelled |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Avid Bioservices;MediPharm Biotech |
| Conditions Approved | Lung cancer |
| Conditions Active | Glioblastoma |
| Conditions Discontinued | na |
| Development Tech | na |
<